Literature DB >> 14765356

Serologic response and antibody-titer decay in adults with pertussis.

Ulrich Heininger1, James D Cherry, Klemens Stehr.   

Abstract

Pertussis is a frequent and significant illness in adults. Because acellular pertussis vaccines for use in adolescents and adults have now been developed, it is important to compare serologic responses in adults after infection with serologic responses in adults after vaccination. We measured IgG and IgA antibodies to 4 Bordetella pertussis antigens at approximately 6-month intervals for 28 months in 11 adults with pertussis. After reaching peak levels, titers of antibody to pertussis toxin decreased more than did titers of antibodies to filamentous hemagglutinin, pertactin, and fimbriae type 1 and type 2. Although studies of adults who have been vaccinated with acellular pertussis vaccines have had shorter follow-up periods than studies of adults with pertussis infection, the antibody decay patterns are similar in both groups.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14765356     DOI: 10.1086/381439

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  19 in total

1.  Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States.

Authors:  Andrew L Baughman; Kristine M Bisgard; Kathryn M Edwards; Dalya Guris; Michael D Decker; Kathy Holland; Bruce D Meade; Freyja Lynn
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

2.  Evaluation of a tetraplex microsphere assay for Bordetella pertussis antibodies.

Authors:  Harry E Prince; Mary Lapé-Nixon; Jose Matud
Journal:  Clin Vaccine Immunol       Date:  2006-02

3.  Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway.

Authors:  Audun Aase; Tove Karin Herstad; Samuel Merino; Kari Torkildsen Brandsdal; Bjørn Peter Berdal; Erja M Aleksandersen; Ingeborg S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2007-05-16

Review 4.  Diagnosis and management of pertussis.

Authors:  Alberto E Tozzi; Lucia Pastore Celentano; Marta Luisa Ciofi degli Atti; Stefania Salmaso
Journal:  CMAJ       Date:  2005-02-15       Impact factor: 8.262

5.  Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity.

Authors:  Audun Aase; Tove Karin Herstad; Samuel Merino; Merete Bolstad; Synne Sandbu; Hilde Bakke; Ingeborg S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2011-06-15

6.  Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters.

Authors:  Ricardo da Silva Antunes; Mariana Babor; Chelsea Carpenter; Natalie Khalil; Mario Cortese; Alexander J Mentzer; Grégory Seumois; Christopher D Petro; Lisa A Purcell; Pandurangan Vijayanand; Shane Crotty; Bali Pulendran; Bjoern Peters; Alessandro Sette
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

7.  Toward a new vaccine for pertussis.

Authors:  John B Robbins; Rachel Schneerson; Joanna Kubler-Kielb; Jerry M Keith; Birger Trollfors; Evgeny Vinogradov; Joseph Shiloach
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-20       Impact factor: 11.205

Review 8.  Laboratory Diagnosis of Pertussis.

Authors:  Anneke van der Zee; Joop F P Schellekens; Frits R Mooi
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

9.  A two-stage experimental design for dilution assays.

Authors:  Jake M Ferguson; Tanya A Miura; Craig R Miller
Journal:  Biometrics       Date:  2019-04-03       Impact factor: 2.571

10.  A comparison of 2 strategies to prevent infection following pertussis exposure in vaccinated healthcare personnel.

Authors:  William P Goins; Kathryn M Edwards; Cindy L Vnencak-Jones; Michael T Rock; Melanie Swift; Valerie Thayer; William Schaffner; Thomas R Talbot
Journal:  Clin Infect Dis       Date:  2012-01-11       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.